Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus - PubMed (original) (raw)

Review

Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus

Chean Yeah Yong et al. Front Microbiol. 2019.

Abstract

Middle East respiratory syndrome (MERS) is a deadly viral respiratory disease caused by MERS-coronavirus (MERS-CoV) infection. To date, there is no specific treatment proven effective against this viral disease. In addition, no vaccine has been licensed to prevent MERS-CoV infection thus far. Therefore, our current review focuses on the most recent studies in search of an effective MERS vaccine. Overall, vaccine candidates against MERS-CoV are mainly based upon the viral spike (S) protein, due to its vital role in the viral infectivity, although several studies focused on other viral proteins such as the nucleocapsid (N) protein, envelope (E) protein, and non-structural protein 16 (NSP16) have also been reported. In general, the potential vaccine candidates can be classified into six types: viral vector-based vaccine, DNA vaccine, subunit vaccine, nanoparticle-based vaccine, inactivated-whole virus vaccine and live-attenuated vaccine, which are discussed in detail. Besides, the immune responses and potential antibody dependent enhancement of MERS-CoV infection are extensively reviewed. In addition, animal models used to study MERS-CoV and evaluate the vaccine candidates are discussed intensively.

Keywords: Middle East respiratory syndrome; animal model; antibody dependent enhancement; coronavirus; vaccine.

PubMed Disclaimer

Similar articles

• Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.
  Tai W, Wang Y, Fett CA, Zhao G, Li F, Perlman S, Jiang S, Zhou Y, Du L. Tai W, et al. J Virol. 2016 Dec 16;91(1):e01651-16. doi: 10.1128/JVI.01651-16. Print 2017 Jan 1. J Virol. 2016. PMID: 27795425 Free PMC article.
• Cross-Protection against MERS-CoV by Prime-Boost Vaccination Using Viral Spike DNA and Protein.
  Choi JA, Goo J, Yang E, Jung DI, Lee S, Rho S, Jeong Y, Park YS, Park H, Moon YH, Park U, Seo SH, Lee H, Lee JM, Cho NH, Song M, Kim JO. Choi JA, et al. J Virol. 2020 Nov 23;94(24):e01176-20. doi: 10.1128/JVI.01176-20. Print 2020 Nov 23. J Virol. 2020. PMID: 32967955 Free PMC article.
• Single-Dose, Intranasal Immunization with Recombinant Parainfluenza Virus 5 Expressing Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Spike Protein Protects Mice from Fatal MERS-CoV Infection.
  Li K, Li Z, Wohlford-Lenane C, Meyerholz DK, Channappanavar R, An D, Perlman S, McCray PB Jr, He B. Li K, et al. mBio. 2020 Apr 7;11(2):e00554-20. doi: 10.1128/mBio.00554-20. mBio. 2020. PMID: 32265331 Free PMC article.
• Vaccines based on virus-like nano-particles for use against Middle East Respiratory Syndrome (MERS) coronavirus.
  Hashemzadeh A, Avan A, Ferns GA, Khazaei M. Hashemzadeh A, et al. Vaccine. 2020 Aug 10;38(36):5742-5746. doi: 10.1016/j.vaccine.2020.07.003. Epub 2020 Jul 11. Vaccine. 2020. PMID: 32684497 Free PMC article. Review.
• An overview of Middle East respiratory syndrome coronavirus vaccines in preclinical studies.
  Zhang N, Shang J, Li C, Zhou K, Du L. Zhang N, et al. Expert Rev Vaccines. 2020 Sep;19(9):817-829. doi: 10.1080/14760584.2020.1813574. Epub 2020 Sep 8. Expert Rev Vaccines. 2020. PMID: 32842811 Free PMC article. Review.

Cited by

• Dissecting humoral immune responses to an MVA-vectored MERS-CoV vaccine in humans using a systems serology approach.
  Weskamm LM, Tarnow P, Harms C, Huchon M, Raadsen MP, Friedrich M, Rübenacker L, Grüttner C, Garcia MG; MVA-MERS-S-CEF study group; Koch T, Becker S, Sutter G, Lhomme E, Haagmans BL, Fathi A, Blois SM, Dahlke C, Richert L, Addo MM. Weskamm LM, et al. iScience. 2024 Jul 8;27(8):110470. doi: 10.1016/j.isci.2024.110470. eCollection 2024 Aug 16. iScience. 2024. PMID: 39148710 Free PMC article.
• Designing of a multi-epitopes based vaccine against Haemophilius parainfluenzae and its validation through integrated computational approaches.
  Ghaffar SA, Tahir H, Muhammad S, Shahid M, Naqqash T, Faisal M, Albekairi TH, Alshammari A, Albekairi NA, Manzoor I. Ghaffar SA, et al. Front Immunol. 2024 Apr 16;15:1380732. doi: 10.3389/fimmu.2024.1380732. eCollection 2024. Front Immunol. 2024. PMID: 38690283 Free PMC article.
• Immunization with V987H-stabilized Spike glycoprotein protects K18-hACE2 mice and golden Syrian hamsters upon SARS-CoV-2 infection.
  Ávila-Nieto C, Vergara-Alert J, Amengual-Rigo P, Ainsua-Enrich E, Brustolin M, Rodríguez de la Concepción ML, Pedreño-Lopez N, Rodon J, Urrea V, Pradenas E, Marfil S, Ballana E, Riveira-Muñoz E, Pérez M, Roca N, Tarrés-Freixas F, Cantero G, Pons-Grífols A, Rovirosa C, Aguilar-Gurrieri C, Ortiz R, Barajas A, Trinité B, Lepore R, Muñoz-Basagoiti J, Perez-Zsolt D, Izquierdo-Useros N, Valencia A, Blanco J, Guallar V, Clotet B, Segalés J, Carrillo J. Ávila-Nieto C, et al. Nat Commun. 2024 Mar 21;15(1):2349. doi: 10.1038/s41467-024-46714-w. Nat Commun. 2024. PMID: 38514609 Free PMC article.
• Porcine Epidemic Diarrhea: Insights and Progress on Vaccines.
  Park JE. Park JE. Vaccines (Basel). 2024 Feb 18;12(2):212. doi: 10.3390/vaccines12020212. Vaccines (Basel). 2024. PMID: 38400195 Free PMC article. Review.
• HIV infection and the implication for COVID-19 vaccination.
  Oyelade T, Raya RP, Latief K. Oyelade T, et al. Public Health Chall. 2022 Sep;1(3):e14. doi: 10.1002/puh2.14. Epub 2022 Jul 29. Public Health Chall. 2022. PMID: 37521727 Free PMC article. Review.

References

1. 1. Adney D. R., van Doremalen N., Brown V. R., Bushmaker T., Scott D., de Wit E., et al. (2014). Replication and shedding of MERS-CoV in upper respiratory tract of inoculated dromedary camels. Emerg. Infect. Dis. 20 1999–2005. 10.3201/eid2012.141280 - DOI - PMC - PubMed
2. 1. Adney D. R., Wang L., van Doremalen N., Shi W., Zhang Y., Kong W. P., et al. (2019). Efficacy of an adjuvanted middle east respiratory syndrome coronavirus spike protein vaccine in dromedary camels and alpacas. Viruses 11:E212. 10.3390/v11030212 - DOI - PMC - PubMed
3. 1. Agnihothram S., Gopal R., Yount B. L., Jr., Donaldson E. F., Menachery V. D., Graham R. L. (2014). Evaluation of serologic and antigenic relationships between middle eastern respiratory syndrome coronavirus and other coronaviruses to develop vaccine platforms for the rapid response to emerging coronaviruses. J. Infect Dis. 209 995–1006. 10.1093/infdis/jit609 - DOI - PMC - PubMed
4. 1. Agrawal A. S., Garron T., Tao X., Peng B. H., Wakamiya M., Chan T. S., et al. (2015). Generation of a transgenic mouse model of middle east respiratory syndrome coronavirus infection and disease. J. Virol. 89 3659–3670. 10.1128/JVI.03427-3414 - DOI - PMC - PubMed
5. 1. Agrawal A. S., Tao X., Algaissi A., Garron T., Narayanan K., Peng B. H., et al. (2016). Immunization with inactivated middle east respiratory syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum. Vaccin. Immunother. 12 2351–2356. 10.1080/21645515.2016.1177688 - DOI - PMC - PubMed

Publication types

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • Frontiers Media SA
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations